Pay in 4 interest-free payments of $6.79 Learn more
Ships within 48 hours · Estimated delivery Sep 27 - Oct 2
The dose-response analysis suggested that doses exceeding 1,000 mg per day were most effective
Safety Comparison# Semaglutide# Well-characterized safety profile across thousands of patients: GI adverse events: 50-70% (mostly mild-moderate, dose-escalation related) Discontinuation due to AEs: ~7% (STEP 1) Boxed warning: Thyroid C-cell tumors (rodent data) Post-marketing signals: Pancreatitis, gallbladder events, ileus (rare) 8+ years of post-marketing surveillance Zovaglutide# Phase 2 safety data (303 patients, 24 weeks): GI adverse events: Present but low severity Discontinuation due to GI AEs: 1.3% (notably low for GLP-1 class) Monthly dosing showed fewer GI events than biweekly dosing No long-term safety data available No post-marketing experience The 1.3% GI-related discontinuation rate is notably lower than typical GLP-1 agonists (5-10%)
Published May 8, 2024
A once-weekly injection that mimics GLP-1 and GIP (like Mounjaro), as well as a third digestive hormone called glucagon, and is currently undergoing phase 3 clinical trials
